Mark E. Robinson

Mark E. Robinson

Auto-generated profile, based on publicly available information

Mark E. Robinson

Center of Molecular and Cellular Oncology, Yale University, New Haven, CT 06511, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cell Metabolism
Verified
Journal Article
Open access
CMClaire E. Macdougall
Claire E. Macdougall
EWElizabeth G. Wood
Elizabeth G. Wood
JLJakob Loschko
Jakob Loschko
VSValeria Scagliotti
Valeria Scagliotti
FCFéaron C. Cassidy
Féaron C. Cassidy
MLM. Paula Longhi
M. Paula Longhi
Visceral adipose tissue (VAT) has multiple roles in orchestrating whole-body energy homeostasis. In addition, VAT is now considered an immune site harboring an array of innate and adaptive immune cells with a direct role in immune surveillance and host defense. We report that conventional dendritic cells (cDCs) in VAT acquire a tolerogenic phenotype through upregulation of pathways involved in adipocyte differentiation. While activation of the Wnt/β-catenin pathway in cDC1 DCs induces IL-10 production, upregulation of the PPARγ pathway in cDC2 DCs directly suppresses their activation. Combined, they promote an anti-inflammatory milieu in vivo delaying the onset of obesity-induced chronic inflammation and insulin resistance. Under long-term over-nutrition, changes in adipocyte biology curtail β-catenin and PPARγ activation, contributing to VAT inflammation.

4 November 2020 in Nature
Verified
Journal Article
Open access
PDF file
JLJaewoong Lee
Jaewoong Lee
MRMark E. Robinson
Mark E. Robinson
NMNing Ma
Ning Ma
DADewan Artadji
Dewan Artadji
MAMohamed A. Ahmed
Mohamed A. Ahmed
MMMarkus Müschen
Markus Müschen
Interferon-induced transmembrane protein 3 (IFITM3) has previously been identified as an endosomal protein that blocks viral infection1,2,3. Here we studied clinical cohorts of patients with B cell leukaemia and lymphoma, and identified IFITM3 as a strong predictor of poor outcome. In normal resting B cells, IFITM3 was minimally expressed and mainly localized in endosomes. However, engagement of the B cell receptor (BCR) induced both expression of IFITM3 and phosphorylation of this protein at Tyr20, which resulted in the accumulation of IFITM3 at the cell surface. In B cell leukaemia, oncogenic kinases phosphorylate IFITM3 at Tyr20, which causes constitutive localization of this protein at the plasma membrane. In a mouse model, Ifitm3−/− naive B cells developed in normal numbers; however, the formation of germinal centres and the production of antigen-specific antibodies were compromised. Oncogenes that induce the development of leukaemia and lymphoma did not transform Ifitm3−/− B cells. Conversely, the phosphomimetic IFITM3(Y20E) mutant induced oncogenic PI3K signalling and initiated the transformation of premalignant B cells. Mechanistic experiments revealed that IFITM3 functions as a PIP3 scaffold and central amplifier of PI3K signalling. The amplification of PI3K signals depends on IFITM3 using two lysine residues (Lys83 and Lys104) in its conserved intracellular loop as a scaffold for the accumulation of PIP3. In Ifitm3−/− B cells, lipid rafts were depleted of PIP3, which resulted in the defective expression of over 60 lipid-raft-associated surface receptors, and impaired BCR signalling and cellular adhesion. We conclude that the phosphorylation of IFITM3 that occurs after B cells encounter antigen induces a dynamic switch from antiviral effector functions in endosomes to a PI3K amplification loop at the cell surface. IFITM3-dependent amplification of PI3K signalling, which in part acts downstream of the BCR, is critical for the rapid expansion of B cells with high affinity to antigen. In addition, multiple oncogenes depend on IFITM3 to assemble PIP3-dependent signalling complexes and amplify PI3K signalling for malignant transformation.

5 March 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LBLigia Simoes Braga Boisserand
Ligia Simoes Braga Boisserand
LGLuiz Henrique Geraldo
Luiz Henrique Geraldo
JBJean Bouchart
Jean Bouchart
MKMarie-Renee El Kamouh
Marie-Renee El Kamouh
SLSeyoung Lee
Seyoung Lee
JTJean-Leon Thomas
Jean-Leon Thomas
Meningeal lymphatic vessels (MLVs) promote tissue clearance and immune surveillance in the central nervous system (CNS). Vascular endothelial growth factor-C (VEGF-C) regulates MLV development and maintenance and has therapeutic potential for treating neurological disorders. Herein, we investigated the effects of VEGF-C overexpression on brain fluid drainage and ischemic stroke outcomes in mice. Intracerebrospinal administration of an adeno-associated virus expressing mouse full-length VEGF-C (AAV-mVEGF-C) increased CSF drainage to the deep cervical lymph nodes (dCLNs) by enhancing lymphatic growth and upregulated neuroprotective signaling pathways identified by single nuclei RNA sequencing of brain cells. In a mouse model of ischemic stroke, AAV-mVEGF-C pretreatment reduced stroke injury and ameliorated motor performances in the subacute stage, associated with mitigated microglia-mediated inflammation and increased BDNF signaling in brain cells. Neuroprotective effects of VEGF-C were lost upon cauterization of the dCLN afferent lymphatics and not mimicked by acute post-stroke VEGF-C injection. We conclude that VEGF-C prophylaxis promotes multiple vascular, immune, and neural responses that culminate in a protection against neurological damage in acute ischemic stroke.

8 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
DIDeena Iskander
Deena Iskander
GWGuanlin Wang
Guanlin Wang
EHElisabeth F. Heuston
Elisabeth F. Heuston
CCChrysi Christodoulidou
Chrysi Christodoulidou
BPBethan Psaila
Bethan Psaila
AKAnastasios Karadimitris
Anastasios Karadimitris
Genotype-phenotype correlations are revealed by bone marrow single-cell RNA sequencing in Diamond-Blackfan anemia.

22 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LCLai N. Chan
Lai N. Chan
MMMark A. Murakami
Mark A. Murakami
MRMark E. Robinson
Mark E. Robinson
RCRebecca Caeser
Rebecca Caeser
TSTeresa Sadras
Teresa Sadras
MMMarkus Müschen
Markus Müschen

9 January 2019 in Oncogene
Verified
Journal Article
Open access
PDF file
KPKatarzyna Parzych
Katarzyna Parzych
PSPaula Saavedra-García
Paula Saavedra-García
GVGabriel N. Valbuena
Gabriel N. Valbuena
HAHibah A. Al-Sadah
Hibah A. Al-Sadah
MRMark E. Robinson
Mark E. Robinson
Holger AunerHolger Auner
Holger Auner
VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we provide evidence that VCP/p97 acts as a regulator of cellular metabolism. We found that VCP/p97 was tied to multiple metabolic processes on the gene expression level in a diverse range of cancer cell lines and in patient-derived multiple myeloma cells. Cellular VCP/p97 dependency to maintain proteostasis was increased under conditions of glucose and glutamine limitation in a range of cancer cell lines from different tissues. Moreover, glutamine depletion led to increased VCP/p97 expression, whereas VCP/p97 inhibition perturbed metabolic processes and intracellular amino acid turnover. GCN2, an amino acid-sensing kinase, attenuated stress signalling and cell death triggered by VCP/p97 inhibition and nutrient shortages and modulated ERK activation, autophagy, and glycolytic metabolite turnover. Together, our data point to an interconnected role of VCP/p97 and GCN2 in maintaining cancer cell metabolic and protein homoeostasis.